Meeting
2014 ASCO Annual Meeting
Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving highly emetogenic chemotherapy (HEC).
Authors
Bernardo Leon Rapoport
The Medical Oncology Center of Rosebank, Johannesburg, South Africa
Bernardo Leon Rapoport , Allen Poma , Mary Lynne Hedley , Robert E. Martell , Rudolph M. Navari
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT01500213
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 9638)
DOI
10.1200/jco.2014.32.15_suppl.9638
Abstract #
9638
Poster Bd #
288
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase III, randomized, double-blind, multicenter, active control study of fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving cisplatin-based highly emetogenic chemotherapy (HEC): CONSOLE.
First Author: Yoshimasa Shiraishi
Poster
2021 ASCO Annual Meeting
A randomized, double-blind, multicenter, phase III study of fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving doxorubicin-cyclophosphamide/epirubicin-cyclophosphamide(AC/EC) based highly emetogenic chemotherapy: CONSOLE-BC.
First Author: Junji Tsurutani
Poster
2014 ASCO Annual Meeting
Safety of rolapitant, a novel NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC).
First Author: Laszlo Urban
Poster
2014 ASCO Annual Meeting
Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderately emetogenic chemotherapy (MEC).
First Author: Ian D. Schnadig